Loading…
← CockpitCompetitor Analysis › STAA STAAR Surgical CompanyOpen in the cockpit ↗

STAAR Surgical CompanySTAACompetitor analysis, valuation and peers

United States · USD·Health Care›Medical Specialties

Maker of implantable collamer lenses (ICLs), a surgical alternative to LASIK for correcting vision, especially in myopia.

Momentum strong 61
Mkt cap
$1.27B
US dollars, full cap
Free float
60%
of shares outstanding
$/day
$19.7M
20-day average traded
Fwd P/E
46.9×
forward earnings
ROIC−WACC
-2.5 pp
WACC 11.0%
Hurdle
+27 pp
Req g minus delivered
Next earnings
98 days
24 Feb 2027
Close · USD$25.35
1D-0.8%
1W-5.0%
1M+13.6%
3M+9.9%
6M-23.3%
YTD+9.8%
1Y-4.3%
ATR %4.8%
Beta0.37
52w lowhigh29.3% off high

What STAAR Surgical does

Maker of implantable collamer lenses (ICLs), a surgical alternative to LASIK for correcting vision, especially in myopia.

The lens is a one-time implant per eye, so sales depend on bringing in new patients through surgeon training and consumer demand rather than repeat purchases. China is its largest market, where patients pay privately, so economic sentiment and local competition matter.

Products and services

  • EVO Implantable Collamer Lens (ICL)
  • Cataract/other intraocular lens products

Customers

  • Ophthalmic surgeons
  • Refractive surgery patients

Where it sits in the supply chain

  • Medical devices
  • Ophthalmic surgical devices
  • Implantable phakic intraocular lenses

What could go right

  • Myopia/refractive surgery adoption growth
  • China/Asia-Pacific market expansion

What could go wrong

  • China market/regulatory concentration risk
  • LASIK remains dominant refractive-surgery alternative

Moat: narrow (IP / patents, brand, regulatory licence). Proprietary Collamer lens material and long track record differentiate ICL from newer competitors.

Headquarters: Lake Forest, California · Founded: 1982 · Employees: 957

Named competitors

STAAR Surgical at a glance

Size STAAR Surgical (STAA) is a United States Health Care company (Medical Specialties) with a market value of $1.27B, the 2081st largest of 3,085 United States companies the cockpit tracks. Shares closed at $25.35 on 18 Nov 2026.

Performance Over six months the shares fell 23.3%, against -14.3% for the median peer and -2.2% for the United States market (cap-weighted) — 8th lowest of 20 in its peer set.

Growth Revenue grew 42.4% over the last twelve months (peer median +10.8%); the operating margin is 6.7% (peer median 15.3%).

Valuation It trades at 46.9× forward earnings against a peer median of 23.9× (2nd most expensive of 16).

Price implies For today's price to make sense, revenue must grow about 35% a year for seven years (Req g). Recent delivered growth is +8%, so the hurdle is +27 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 2.5 points below its cost of capital (11.0% WACC).

Short interest Short interest is 7.3% of the free float (30 Oct 2026).

Next results Next results expected around 24 Feb 2027 (exchange calendar; dates can move).

Relative performance

608010021 May 202621 Aug 202618 Nov 2026Peer median 86STAA 77
Six months, rebased to 100: STAAR Surgical against the median of its 20 peers (local-currency closes).

STAAR Surgical financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$328M$239M$314M$322M$284M
Revenue growth—-24%-3%+13%—
Gross profit$234M$177M$235M$253M$223M
EBITDA$33.1M-$37.2M-$5.72M$33.2M$48.3M
Net income$530,000-$80.4M-$20.2M$21.3M$39.7M
Free cash flow$17.8M-$40.0M-$7.67M-$3.59M$17.6M
Capital expenditure$3.55M$5.82M$23.4M$18.2M$18.1M
Total debt$33.6M$38.4M$38.7M$35.8M$31.0M

Quarterly statements and history in the cockpit →

STAAR Surgical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%-25%0%+25%-40%-20%0%+20%NVCR6882893006336887586881983005952675TNDM688161CNMD300406PRCT300298DRTSATEC214150STAA6-month return →1-month return →
Up and to the right = strong over both horizons. STAAR Surgical is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%50×100×6882893006336887586881983005956880502675688161CNMDATEC214150STAARevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. STAAR Surgical is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%688758688198300595688050688161CNMD300406300298300049ELN214150STAAGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. STAAR Surgical is the large dot.

STAAR Surgical competitors and peer comparison

Head to head with its named competitors (STAA vs JNJ vs ALC.SW vs BLCO.TO)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
STAAR Surgical STAA$1.27B-23%+42%7%46.9×35.1%
Johnson & Johnson JNJ$656B+20%+8%26%24.2×3.7%
Alcon ALC.SW$36.9B+18%+1%12%21.5×12.2%
Bausch + Lomb BLCO.TO$7.41B+35%+11%9%18.3×12.0%

How STAAR Surgical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

STAAR Surgical against its 20 peers (data as of 18 Nov 2026)
MeasureSTAAPeer medianRank in peer set
1-month return+13.6%-5.1%2nd highest of 21
6-month return-23.3%-14.3%8th lowest of 20
Distance from 52-week high-29.3%-39.9%6th highest of 21
Revenue growth (TTM)+42.4%+10.8%2nd highest of 19
Operating margin6.7%15.3%10th lowest of 20
Forward P/E46.9×23.9×2nd most expensive of 16
Growth the price implies (Req g, 7 yrs)35.1%10.3%most demanding of 12
Growth delivered (Del g)+7.9%+16.5%3rd lowest of 12
Hurdle (Req g minus delivered)+27.2 pp-8.1 ppmost demanding of 12
ROIC minus cost of capital-2.5 pp+0.9 pp8th lowest of 20
EV / EBITDA33.2×12.3×most expensive of 6
Net debt / EBITDA-5.2×-0.9×2nd least indebted of 7

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
STAAR Surgical STAAUnited States$1.27B-23%+42%7%46.9×35.1%+7.9%
NovoCure NVCRUnited States$1.25B-40%+13%-17%n/an/an/a
Sansure Biotech 688289.SSChina$1.24B-17%-1%1%35.6×n/an/a
Sonoscape Medical 300633.SZChina$1.31B-10%+18%4%34.7×n/an/a
Suzhou Sepax Technologies 688758.SSChina$1.31B+8%+28%40%46.0×22.8%+23.6%
Beijing Balance Medical Technology 688198.SSChina$1.31B-32%+10%28%41.5×20.7%+27.6%
Ovctek China 300595.SZChina$1.33B-25%0%28%19.4×8.3%+16.5%
Eyebright Medical Technology (Beijing) 688050.SSChina$1.21B-16%+21%16%23.9×10.3%+40.3%
Shenzhen Edge Medical 2675.HKHong Kong$1.21B-51%+132%2%120.2×n/an/a
Tandem Diabetes Care TNDMUnited States$1.19B+13%+7%-2%n/an/an/a
Shandong Weigao Orthopaedic Device 688161.SSChina$1.14B-29%-6%18%24.9×11.3%-3.5%
CONMED CNMDUnited States$1.43B+30%+2%2%10.4×31.6%+9.8%
Beijing Strong Biotechnologies 300406.SZChina$1.13B-4%-4%36%18.2×1.7%+9.9%
PROCEPT BioRobotics PRCTUnited States$1.45B-10%+17%-34%n/an/an/a
Sinocare 300298.SZChina$1.45B+4%+7%6%21.5×9.5%+18.3%
Inner Mongolia Furui Medical Science 300049.SZChina$1.45B-31%+11%25%41.9×2.9%+14.6%
Alpha Tau Medical DRTSUnited States$1.11B+7%n/an/an/an/an/a
El.En ELN.MIItaly$1.46B+11%+3%15%22.0×10.7%+7.7%
Alphatec ATECUnited States$1.10B-14%+15%-3%15.1×n/an/a
Freenome FRNMUnited States$1.08Bn/an/a36%n/an/an/a
CLASSYS 214150.KSSouth Korea$1.08B-60%+16%43%13.7×-9.2%+34.5%

Questions

Who are STAAR Surgical's main competitors?
Named competitors: Johnson & Johnson (Vision) (JNJ), Alcon (ALC.SW), Bausch + Lomb (BLCO.TO). The cockpit's measured peer set (industry) also includes NovoCure (NVCR), Sansure Biotech (688289.SS), Sonoscape Medical (300633.SZ), Suzhou Sepax Technologies (688758.SS), Beijing Balance Medical Technology (688198.SS), Ovctek China (300595.SZ).
Is STAAR Surgical expensive compared with its peers?
On forward p/e it trades at 46.9× against a peer median of 23.9×, 2nd most expensive of 16 in its peer set. For today's price to make sense, revenue must grow about 35% a year for seven years (Req g). Recent delivered growth is +8%, so the hurdle is +27 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has STAAR Surgical stock performed?
Over six months to 18 Nov 2026 the shares returned -23.3% against -14.3% for the median peer; over one year -4.3%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.